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Melanoma is a cancer of the melanocytes (pigment-forming skin cells) and it takes 
more lives today than ever before; treatment methods simply cannot keep up with 
the climbing rate of incidence (1). Although melanoma overall has a 5-year survival 
rate of 91% and represents only 5% of skin cancers, it is still responsible for 2. 7 fold 
more deaths than all other skin cancers (30). Advancements in the understanding of 
oncogenic signaling, however, have led to a promising new wave of melanoma 
treatments (3). These treatments center around BRAF, a gene that when mutated, is 
believed to be a cause of melanoma. BRAF, like many genes is transcribed into a 
molecule called mRNA, which is then translated into the functional product, a 
protein. One of these drugs, Vemurafenib, was associated with a 63% reduction in 
death when compared to decarbazine (a common chemotherapy drug) in a phase III 
study (5). Vemurafenib gets is name from its function, V600E mutant BRAF 
inhibition. Unfortunately, as with most BRAF-V600E inhibitors, Vemurafenib's high 
initial success rate is followed quickly by resistance to the drug (3). While 
Vemurafenib acts as a protein kinase inhibitor for the mutated protein product of 
V600E, the treatment proposed by this paper is to instead target the mRNA of 
V600E for degradation by siRNA. This treatment will focus on stopping the problem 
one step earlier in the process than inhibitors such as Vemurafenib. If siRNA is able 
to knockdown BRAF-V600E, it could be used alongside drugs such as Vemurafenib 
to improve the current treatment of melanoma. 
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Introduction 
The "Battle Against Cancer" is a phrase everyone in the modern world is 
familiar with. It is an ongoing struggle that began with the discovery of cancer by 
ancient peoples. It has not been until the last century however, that any progress 
has been made against it. Every major advancement that has been made in treating 
this disease has come directly from changes in the basic understanding of cancer. 
The understanding of cancer is expanded through research advancements and then 
application of those breakthroughs gleaned from research. The focus of this paper 
will be to use the understanding of a specific form of cancer, V600E induced 
melanoma, to propose a new treatment for it. 
Melanoma is a cancer of the melanocytes (pigment-forming skin cells) and it 
takes more lives today than ever before; treatment methods simply cannot keep up 
with the climbing rate of incidence (1). Although melanoma overall has a 5-year 
survival rate of 91% and represents only 5% of skin cancers, it is still responsible 
for 2.7 fold more deaths than all other skin cancers (30). The key to the overall high 
survival rate is early detection, effective staging, and then appropriate treatment 
based on the staging. Treatment based on staging is important in the balance of 
minimizing damage to tissue against preventing recurrence of the cancer. Melanoma 
is staged by the size of the tumor and the degree of spread of the cancer. In stage I 
the thickness is less than l.Omm and may be ulcerated. For stage II, the tumor may 
be up to 4.0mm and ulcerated but not metastasized. Stage Ill melanomas have 
spread to the lymph nodes but not other areas of the body. In general, earlier stages 
of melanoma can be cured through excision alone because the cancer is a solid mass 
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and can be removed all at once. As the stages progress, excision must be paired with 
other cancer treatment therapies such as: radiation, chemotherapy, 
immunotherapy, and targeted therapies because the cancer has spread deeper into 
the tissue (2). As with all cancers, serious problems arise when the cancer is not 
detected early or when initial treatment is not successful. Stage IV melanoma is 
more difficult to treat than the other stages because it has spread to other places on 
the body. Since the cancer has already spread, removal of local cancer alone is not 
enough. This is also a problem in cases of recurrent melanoma. The cancer may not 
have spread to other areas, but comes back after removal. 
Advancements in the understanding of oncogenic signaling, however, have 
led to a promising new wave of melanoma treatments (3). These treatments center 
around BRAF, a gene that when mutated, is believed to be a cause of melanoma. 
BRAF, like many genes is transcribed into a molecule called mRNA, which is then 
translated into the functional product, a protein. B-Raf, the protein product of the 
BRAF gene, is involved in a phosphorylation cascade that contributes to controlling 
the cell cycle. The cascade is a series of proteins starting with EGF and EGFR at the 
membrane, followed by GBR2, SOS and RAS then RAF, MEK and ERK. This chain 
relays a message from a signaling protein on the surface of the cell to instruct the 
cell's DNA to produce a specific protein. The protein usually promotes growth, such 
as cell division. Any malfunction in this pathway can lead to cancer. Mutant B-Raf 
(BRAF-v600E) has been found in 50% of melanomas, more than any other mutation, 
and has shown a 4% increase in the chance of the cancer recurring (4). BRAF-
V600E's apparent role as a cause for melanoma has prompted the creation of new 
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drugs designed to target and inhibit BRAF-V600E. BRAF-V600E-targeting inhibitors 
have already shown the ability to reduce tumors. 
One of these drugs, Vemurafenib, was associated with a 63% reduction in 
death when compared to decarbazine (a common chemotherapy drug) in a phase III 
study (5). Vemurafenib gets is name from its function, V600E mutant BRAF 
inhibition. Unfortunately, as with most BRAF-V600E inhibitors, Vemurafenib's high 
initial success rate is followed quickly by resistance to the drug (3). The chance of 
surviving melanoma could be increased if treatment with Vemurafenib was followed 
by a treatment that was able to stop Vemurafenib-resistant cells from proliferating. 
To slow the growth ofVemurafenib resistant cells, the combined treatment would 
need to have a different mode of action. While Vemurafenib acts as a protein kinase 
inhibitor for the mutated protein product ofV600E, the treatment proposed by this 
paper is to instead target the mRNA ofV600E for degradation by siRNA. 
Antisense siRNA's are ~100 base pair ds-RNA molecules that are able to 
prevent translation of a target mRNA. After the protein, Dicer, separates double-
stranded siRNA's, the guide strand associates with the RNA-induced silencing 
complex (RISC). Because of the guide strand's ability to base pair with the target 
mRNA, the siRNA-RISC complex is able to distinguish between cognate and non-
cognate RNA and target the cognate RNA, i.e the one that encodes the protein, for 
degradation. The objective of this research is to show siRNA can be introduced to a 
BRAF-V600E expressing cell and knockdown the gene. Since the mutant mRNA will 
be degraded, mutated proteins will not be transcribed. This treatment will focus on 
stopping the problem one step earlier in the process than inhibitors such as 
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Vemurafenib. The justification for this treatment is that it addresses a possible cause 
of resistance to protein inhibitor treatment. One hypothesis on the development of 
resistance to BRAF-V600E inhibiting drugs is copy number gains (additional copies 
of the gene are present in the DNA) of mutant BRAF (6) . Resistance occurs when 
more proteins are produced than can be inhibited by the dose ofVemurafenib. This 
problem could be overcome if the mRNA was targeted instead of or in addition to 
the protein product itself. 
Literature Review 
While today there is no "cure" for cancer, for much of history there has been no 
treatment at all. The first step to treating a malady is diagnosing it. In ancient times, 
even that was a tall order as next to nothing was known about cancer. Those 
cultures that were able to identify it would come to claim it was incurable or that 
the best course of treatment was no treatment at all. 
Scrolls from ancient Egypt have been found suggesting the authors were familiar 
with cancer. They likely knew nothing about the disease but they were able to 
observe its symptoms. The scrolls depict people with tumors in their breasts and the 
scrolls detail that this malady has no cure (21 page 40, 30). 
The ancient Greeks were familiar with symptoms of cancer as well and had an 
insight into treating it that the Egyptians may not have had. Cancer received its 
name from the Greek physician Hippocrates. He named it Cancer or "crab" for the 
fingerlike projections that can be seen streaking under the skin from tumors (21 
page 47). Galen, another Greek physician gave it the name "Onkos" for its 
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characteristic swelling (21 page 47). Both men believed cancer to be a humoral 
disease. They believed the body was composed of"humors" (vital liquids), and that 
cancer arose from a humor, a black bile. This incorrect belief was held for centuries 
and mislead many physicians. However, some good came out of this. The 
recommended treatment for cancerous lesions was not to attempt to treat them. 
This was sound advice since recurrence rate after extracting a tumor is high and at 
the time, there were no ways to operate without causing the patient extreme pain 
and distress. Ancient peoples took the first step in defeating cancer, which is to 
identify it. A problem cannot be solved until it is first identified. The Greeks also 
made an important evaluation that removal of a tumor alone is not a cure for cancer 
because it will only come back. The treatment was derived directly from what was 
understood about the disease and the ability to treat it at the time. 
Doctors followed the advice of the Greeks for centuries. They did the best they 
could for a patient with cancer, which was nothing. It was not until people learned 
to take a look at the body themselves that the first step could be take to effectively 
treat cancer. In the 16th century, a leap was made in the understanding of cancer, 
which resulted directly from advancement in the understanding of the human body. 
Finally, medicine started to step away from the ideas of humors in the body and take 
an initiative to describe what was truly there. In 1533, Andreas Vesalius began 
drawing one of the first accurate and exhaustive depictions ofthe human body, 
depicting the venation and nervous systems. He drew only what he was able to 
observe himself, which did not include any of the humors described by the Greeks 
(21 page 53). A peer ofVesalius, Mathew Baillie illustrated another account of 
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human anatomy "The Morbid Anatomy of Some of the Most Important Parts of the 
Body." His drawings depicted illness in the body, including cancerous tumors, with 
the same objectiveness that Vesalius had used in his illustrations of the "healthy" 
body. Baillie also, saw no signs of humors in the body, and importantly for the 
understanding of cancer saw no black bile around tumors (21 page 53). 
The new understanding of anatomy led to further curiosity and exploration of 
the body, usually carried out on animals or cadavers. John Hunter, Bailie's uncle, 
studied tumors and developed techniques to remove them and from corpses. He 
described them as "movable" or not. His idea of "movable" tumors would later 
become instrumental in the staging of tumors. However, the understanding of 
Cancer outpaced the ability to treat it. For even with the knowledge of when the 
removal of a tumor was less likely to result in reoccurrence, these techniques could 
not be easily performed on conscious patients and the risk of infection was high due 
to the traditions of poor sanitation in medicine. With the advent of ether for 
anesthesia and soap for sanitation, surgeons were able to start removing lesions 
with some success. The ability to treat cancer was again dependent on the 
knowledge of the disease and our ability to treat based on that knowledge. 
The first of the theories to replace the Greek humor theory was the blastema 
theory. This theory correctly suggested that lesions consisted of rapidly dividing 
cells and were able to spread by cells traveling to other parts of the body. Three men 
were responsible for these ideas. In 1838 Johannes Muller suggested lesions were 
composed of cells and that they arose from budding agents, blastemas (7). While he 
was wrong about the origin of the lesions the idea that tumors were made of cells 
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was crucial to furthering our understanding of the disease. RudolfVirchow put 
forward the idea that cancer spread from preexisting tumors through some 
secretion of the tumor in 1863(7). Karl Von Rokitansky was able to modify 
Virchow's theory by correctly pointing out that tumors spread through malignant 
cells (8) . The idea that cancer was caused by subdividing cells paved the way for 
treatment outside of tumor excision. 
The 1895 discovery of X-Rays revolutionized medicine. The ability to see into the 
body from the outside provided unprecedented abilities to diagnose patients. For 
the treatment of cancer, the discovery of radiation led to a treatment still used 
today, one that is able to target rapidly dividing cells. (21 page 75) Unfortunately 
since radiation is able to kill cancer cells by destroying their DNA is it also 
dangerous to regular cells. Around the same time another treatment arose that took 
advantage of our new knowledge that cancer comes from rapidly dividing cells. 
Chemotherapy, which is also used today, is the use of chemicals to stop the growth 
of cancer cells. The most common strategy is to remove some metabolite a cancer 
cell would need to grow and divide. The reduction of the metabolite leads to slowed 
growth of cancer. However, normal cells depend on the same resources as cancer 
cells, so chemotherapy drugs have severe side effects on normally dividing cells. 
These two new treatments were able to go beyond simply excising lesions by taking 
advantage of new understanding of cancer and applying it through other 
breakthroughs in biotechnology. These treatments are effective at targeting rapidly 
diving cells, making them good at stopping the growth of cancer but also good at 
killing normal cells in our body that are naturally quick-dividing. For example, cells 
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in the gut, blood cells in the bone marrow, and hair follicle cells. This is why you see 
the common side effects-of hair loss in chemotherapy. The next breakthroughs in 
cancer treatment will be ones that are even better at stopping cancer cells 
exclusively. The treatments will depend on knowing just what makes a cancer cell 
different that a normal cell. Enter virology. 
Virology, the study of viruses has produced countless breakthroughs in 
medicine. Obviously, it has led to treatments of viral diseases, but it has also 
produced valuable information into the mechanisms of cancer. Virology gives us 
insight into the true nature of why cancer cells divide rapidly; it is a result of the 
relationship between cancer causing and cancer suppressing genes. 
In 1908, Vilhelm Ellermann and Olaf Bang of Denmark were able to infect 
chickens with leukemia through injection of a cell-free filtrate. At the time, they did 
not know leukemia was a cancer. However, it later was important for showing 
cancer was caused by a non-cellular agent (9). In 1911 scientists knew the paradigm 
of our understanding of cancer had shifted when cancer was caused in a similar way 
in chickens though a virus known as the Rous Sarcoma Virus (RSV). The experiment 
proposed a viral origin for cancer (10). However, it was thought that the discovery 
may not apply to humans because chickens are a poor human model. 
That thought changed though in the 1930's when two experiments were able to 
show a similar results in rabbits. First, an experiment by Richard Shope and Weston 
Hurst showed that rabbits could be vaccinated against a papilloma virus. 
Experimental groups were injected with both infectious and non-infectious 
solutions intravenously or into the body cavity. The solutions were made from 
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tissue infected with rabbit papilloma. These rabbits and control rabbits were then 
exposed to the virus 20 days later. All vaccinated rabbits showed immunity or 
resistance to the exposure (11). Then a 1935 experiment by the Laboratories of The 
Rockefeller Institute for Medical Research showed that papillomas caused by the 
virus Shope used were cancerous (12). They determined this observing rabbits that 
developed papillomas after being exposed to the virus. At the time the paper was 
published, over 50 malignant tumors had been found in 8 of the rabbits. A viral 
origin for cancer had now been shown to apply to mammals. A 1936 experiment by 
Bittner helped support this by providing data from a mouse tumor virus. 
Adenoviruses were finally shown to cause cancer in lab conditions in 1962 (14). 
Adenoviruses are a family of viruses that are classified by being found in human 
adenoids. In 1962 Trentin was looking for human, cancer-causing viruses by 
injecting filtrates of known human viruses into hamsters. Hamsters injected with 
human type 12 adenovirus had a significantly high incidence of malignant tumors. 
The same year a rhesus monkey virus, SV40 (Simian virus 40) was shown to cause 
tumor formation (15). Defining a viral origin for cancer was able to directly lead to 
the prevention of those virally induced cancers. For example the Human Papilloma 
Virus (HPV) vaccine is able to prevent cancer that can result from HPV infection. 
However, this was not all virology had to offer for our understanding or treatment 
of cancer. 
Besides providing a possible cause for cancer in the form a virus, virology has 
also been invaluable in establishing the understanding of the role genes play in 
cancer. In 1970 Dues berg and Vogt were able to compare two strands of RSV, one 
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that caused cancer and one that did not, to identify the specific cancer-causing gene 
(17). They isolated avian sarcoma virus B77 (a virus known to cause cancer in 
birds) from chicken tumors. They then created experimental groups of the virus by 
exposing it to UV radiation. The radiation exposure would cause the virus to mutate. 
By determining which specific gene was required to remain intact for the virus to 
cause cancer, Dues berg and Vogt were able to identify which gene was the 
oncogene (cancer causing gene). This experiment set the precedence for discovering 
oncogenes. In 1976 Stehelin, Varmus, Bishop, and Vogt found genes that caused 
tumors in birds and were closely related to genes normally present in bird DNA 
(18). They were able to establish that cancer can be caused by mutations in normal 
genes; these genes are called proto-oncogenes. The next breakthrough was 
connecting that proto-oncogenes are often genes connected with regulating cell 
growth and division (16). Common proto-oncogenes include: RAS, WNT, MYC, ERK, 
and TRK. These protein products of these oncogenes are all part of signaling 
pathways that regulate cell growth or division. Mutations in these genes lead to 
proteins that will not do their job correctly. When these mistakes occur, they lead to 
cells dividing out of control and cancer develops. 
In the 2000's strides were made in refining the molecular model for how 
proteins that come from oncogenes promoted uncontrolled growth (16). P53 is one 
of the most important oncogene genes because a p53 mutation is present in 50% of 
cancers. Given its great importance, its discovery as on oncogene was crucial. 
However at the time of the discovery, its full significance was not known (19). In 
1989 the P53 gene was found to produce a protein that suppressed tumor formation 
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(20). This means its normal function is to stop tumor growth and a mutation results 
in its inability to function this way. The difference between P53 and other 
oncogenes is that most oncogenes signal the cell to divide, whereas P53 signals the 
cell to stop diving or to self-destruct. These discoveries led to the understanding of 
the relationship between tumor causing and tumor suppressing genes. This 
knowledge is on the current battlefield of the fight against cancer; it being used to 
develop the treatments of tomorrow. The objective of this paper is to use the 
understanding of the cause of cancer by oncogenic products to develop the next 
wave of treatments, specifically a treatment for malignant melanoma. 
Methods 
The objective of this proposed experiment is to show that siRNA can target 
mutant BRAF-V600E RNA for degradation. Two human cell culture lines will be used 
in this experiment, one expressing wild type BRAF and one expressing V600E. Three 
siRNA treatments will be compared. BRAF mRNA targeting siRNA will be the 
positive control because the literature has demonstrated the ability of siRNA to 
knockdown this gene. V600E mRNA targeting siRNA will be the experimental group. 
Knockdown in this group will support siRNA as a viable treatment. An siRNA with 
the same nucleic acid composition of the experimental group but in a non-cognate 
or random sequence will be used as the negative control. A lack of knockdown will 
show that it was ability of the siRNA to bind the target mRNA that led to knockdown. 
All treatments will consist of predesigned siRNA obtained from Thermo Fisher 
Scientific (22). Five replicates of each treatment will be transfected into both wild 
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type BRAF and V600E expressing cells by lentiviral HIV vectors containing the 
siRNA treatments and an indicator sequence. 
Knockdown of B-Raf and mutant V600E protein and will be assessed by 
quantitative, western blots. The SDS page will use RIPA and Laemmli buffers and the 
gel will be 7.5% given the size of BRAF, 84,437Da (24). Li-Cor imaging software will 
be used to compare the expression levels of protein. The primary antibody for BRAF 
will be mouse anti-BRAF antibody purchased from Roche (25) and the secondary 
antibody will be IRDye 800CW goat anti-mouse IgG and be purchased from Li-Cor 
(28). The primary antibody for V600E will be a mouse anti-BRAF V600E antibody 
purchased from Roche (25). The secondary antibody will be IRDye 680RD goat anti-
mouse IgG (28). Ideally, V600E mRNA targeting siRNA will show reduced 
expression ofV600E mutant protein but not of normal BRAF. To further support 
that siRNA is able to target V600E for degradation and that siRNA is a viable 
treatment, a phosphospecific western blot for ERK will be performed. ERK and 
phosphorylated ERK will be assessed via quantitative western blots as shown by 
Charles Adelman et al. (27). Primary antibodies will be rabbit anit-phospho-ERKl/2 
(D13.14.4E) and mouse anti-total-ERKl/2 (3A7) respectively and will be purchased 
from Cell Signaling (27). Secondary antibodies will be IRDye 680RD goat anti-rabbit 
IgG and IRDye 800CW goat anti-mouse IgG and be purchased from Li-Cor (28). Since 
ERK is a down stream phosphorylation product of BRAF, V600E protein reduction 
should result in ERK not being phosphorylated. If ERK is not phosphorylated it will 
support that the treatment was effective in targeting of normal BRAF or V600E and 
that the cell will not be signaled to divide out of control. 
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Discussion 
These experiments could lead to a variety of potential outcomes. Ideally the 
positive control, predesigned BRAF siRNA will knockdown BRAF and/or V600E, the 
negative control random sequence will knockdown neither, and the experimental 
will knock down V600E but not normal BRAF. Significance would be determined by 
95% confidence intervals of data from the quantified western blots. These results 
would support that siRNA can be used to target mutant BRAF and pave the way for 
future research and possible treatments based on this method. Future studies could 
include rPCR to assess and further support that BRAF or V600E RNA has been 
degraded. Animal trials would be used to determine if delivery of the vector is 
possible in considering this for clinical trials. If siRNA is shown to knock down 
mutated BRAF and inhibit phosphorylation of a downstream target, a cell 
proliferation assay will be used to determine if siRNA affects the rate of 
proliferation and if cells develop resistance to siRNA treatment as they do to 
existing BRAF-V600E inhibitors. Further, global inhibition of BRAF potentially 
presents serious side effects. Therefore, additional studies should be performed to 
create siRNA variants, which can preferentially bind to mutant BRAF transcripts 
versus wild-type transcripts. Administration techniques for BRAF cognate siRNA as 
a medication will also be developed with the objective of delivering the siRNA to 
cancerous melanoma cells and not non-cancerous, healthy cells. For example, 
techniques similar to the DPC (Dynamic polyconjuagates) of Rozema et al.(29) could 
potentially be used as delivery systems for these siRNAs. 
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Despite a greater understanding of the physiology of cancer, nearly 1,000,000 
people are living with melanoma and an estimated 10,000 died from it last year 
(National Cancer Institute). Drugs that inhibit mutant 8-Raf show promise in 
helping treat melanoma but have a shortcoming in that the cancer quickly becomes 
resistant to them. If siRNA is able to knockdown BRAF-V600E, it could be used 
alongside drugs such as Vemurafenib to improve the current treatment of 
melanoma. This treatment is limited by its ability to only treat cells susceptible to 
transfection by synthetic oligo-nucleotides. It will not be a cure for cancer, but when 
combined with other therapies could provide more efficient treatment and serve as 
a step towards understanding and ultimately beating cancer. 
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